Merck in Germany was possibly the earliest company to move in this direction. Originating as a pharmacy founded in Darmstadt in 1668, it was in 1827 that Heinrich Emanuel Merck began the ...

She will become executive director of global public policy and stakeholder engagement with Merck Animal Health ... Dominguez worked for Sen. Martin Heinrich, D-N.M. Robert Thurber is retiring ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

Endeavor chief executive Ari Emanuel has officially hit billionaire status after shares in the massive media agency soared over the past year. Bloomberg’s Billionaire Index crowned Emanuel with ...

CNN said it hired Rahm Emanuel, the former Obama advisor and Chicago mayor, as a senior commentator on political and global affairs. Emanuel most recently served as U.S. Ambassador to Japan.

Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...